Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Dynavax Technologies Corp. is positioned favorably in the biopharmaceutical sector, primarily due to its robust vaccine response rates for its 100ug shingles vaccine candidate, which are comparable to those of Shingrix while exhibiting significantly better tolerability. The encouraging results related to the tolerability and CD4+ T-cell responses for the candidate Z-1018 further strengthen the company's outlook in the vaccine market. These positive developments align with Dynavax's focus on leveraging its innovative Toll-like Receptor Immune Modulation Platform, solidifying its potential for revenue growth from its novel vaccines and established products like HEPLISAV-B and CpG 1018.

Bears say

Dynavax Technologies Corp faces significant risks related to the efficacy and safety of its clinical candidates, as failures could hinder regulatory approval and subsequent commercialization, negatively impacting revenue potential. Additionally, market conditions, strong competition, and internal factors may further complicate the commercialization of its proprietary candidates, putting Dynavax at a strategic disadvantage. The possibility of unsuccessful partnership negotiations for its product candidates also raises concerns regarding future growth and financial stability, contributing to a negative outlook on the company's stock.

Dynavax Technologies (DVAX) has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Hold based on their latest research and market trends.

According to 4 analysts, Dynavax Technologies (DVAX) has a Hold consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.